PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)5 November 2025 – Theon International Plc (THEON) is pleased to announce the evolution of the €10 million investment announced in October 2024 for developing new platform-based products. As a result of a joint engineering collaboration between THEON and Shock EO Systems Ltd (ShockEOS) R&D teams over the past 12 months, THEON has received an initial order for several sample units of its newly developed stabilized multi-sensor platform optronics system from a European Defense Prime. These samples will be used for the full qualification of the system on a remote weapon system over the coming months, at the end of which an extensively large order for serial production is expected to be placed. Theon was selected by the Defense Prime based on its established Design and Development...

Villers-lès-Nancy, 5 November 2025 – 6:00 PM (CET) PRESS RELEASE Revenue at 30 September 2025: €172.2m+8.9% on a reported basis and +7.3% like-for-likeGroup revenue at 09/30/2025 (€m) 2024Reported basis 2025Reported basis Change /Reported basis of which external growth Like-for-like change(organic growth)Q1 53.3 57.0 3.7 6.9% 0.5 3.2 5.9%Q2 54.7 58.9 4.3 7.8% 0.5 3.8 6.9%Q3* 50.2 56.2 6.1 12.1% 1.4 4.7 9.4%Total 158.2 172.2 14.0 8.9% 2.4 11.6 7.3%* Unaudited At September 30, 2025, the Equasens Group (Euronext Paris™ – Compartment B – FR 0012882389 -EQS), a leading provider of digital solutions for healthcare professionals, reported revenue of €172.2m, up 8.9% on a reported basis and 7.3% like-for-like compared with the same period in 2024. Q3 was particularly strong, with like-for-like-growth...

Third-quarter revenue of €216.8 million, down slightly by -3.9%Continued sequential improvement quarter after quarter (-12.3% in Q1, -6.7% in Q2)Excluding Connectivity in France, Group revenue up by +3.4% in Q3Energy up +30.8% (+47.5% in France), representing 22% of Group’s Q3 revenue Resumption of fiber roll-out activities in Belgium Germany: revenue up by +10.1% Other Countries segment: strong growth in Italy (+22.3%), continued rationalization in Spain and the United KingdomConnectivity business in France (14% of Group revenue): accelerated adaptation measuresRevenue down -32.1% in Q3 Transformation of the operating model underway, with effects expected in early 2026  9 months Q3In millions of euros 2025 2024 % change 2025 2024 % changeGroup 684.2 742.6         (7.9%) 216.8 225.4         (3.9%)Benelux 262.0 278.7         (6.0%) 80.6 82.1         (1.9%)France 227.6 270.2 (15.8%) 73.3 81.7         (10.3%)Germany 71.3 60.1         +18.7% 24.0 21.8 +10.1%Other...

At a board meeting on 5 November 2025, the Board of Directors and the CEO approved the interim consolidated financial statements of the Kvika banki hf. (“Kvika” or “the bank”) for the third quarter and first nine months of 2025. Highlights of performance in the second quarter (Q3 2025)Profit before tax amounted to ISK 1,969 million, compared to ISK 1,813 million in Q3 2024, an increase of ISK 156 million or 8.6%. Post-tax profit from continuing operations of the Kvika group amounted to ISK 1,472 million in Q3 2025, compared to ISK 1,398 million in Q3 2024, an increase of ISK 74 million or 5.3%. Net interest income amounted to ISK 2,953 million in Q3 2025, compared to ISK 2,429 million in Q3 2024, an increase of ISK 524 million or 21.6%. Net interest margin was 4.0% in Q3 2025, compared to 3.7% in Q3 2024. Net fee and commission income...

MONTREAL, Nov. 05, 2025 (GLOBE NEWSWIRE) — Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) announces that the release of the 2025 third quarter results will take place on Friday, November 7, 2025, at 11 a.m. Financial analysts and investors are invited to attend a conference call during which the financial results will be presented.Date and time     Friday, November 7, 2025, at 11 a.m. ET   To attend the conference      Webcast link: https://edge.media-server.com/mmc/p/vr57urmw       To attend the event by phone: Click here to register for the earnings call. Once you have completed your registration, you will receive a confirmation email containing the link and your personal PIN to connect to the call. If you lose this link and your PIN, you will be able to register again. You must register if you...

DALLAS, Nov. 05, 2025 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) today announced its financial and operational results for the third quarter of 2025, as well as a quarterly cash dividend of $0.03 per share. Due to the pending merger (the “Merger”) with California Resources Corporation (“CRC”), Berry will not post supplemental slides or host a conference call to discuss its quarterly results. HighlightsProduced 23.9 thousand barrels of oil equivalent per day (“MBoe/d”) (91% oil) Brought online operated 4-well horizontal Uinta pad in August; achieved a peak pad IP30 rate of 4,000 Boe/d (93% oil) Reported net loss of $26 million, or $0.34 per diluted share, and Adjusted Net Loss(1) of $6 million, or $0.08 per share Generated operating cash flow of $55 million, Adjusted EBITDA(1) of $49 million...

– Orders decreased 5% year over year, but increased 5% sequentially– Restructuring initiatives expected to achieve $1.5 million annualized savings by mid-2026– Declared a quarterly cash dividend of $0.20 per share LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) — Natural Health Trends Corp. (NASDAQ: NHTC), a leading direct-selling and e-commerce company that markets premium quality personal care, wellness and “quality of life” products under the NHT Global brand, today announced its financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsRevenue of $9.5 million decreased 11% compared to $10.7 million in the third quarter of 2024 in part due to the timing of a product promotion and the presale of our new skincare line at the end of September 2025 in Hong Kong. Operating loss was $495,000...

Overall Third Quarter Sales Increased 3.7% to $14.8 Million, Compared to $14.3 Million for the Third Quarter of 2024Net sales for the third quarter of 2025 were $14.8 million, up 3.7% compared to $14.3 million for the third quarter of 2024  Building Supply segment increased by $476,000 or 5.4%, to $9.3 million, compared to $8.8 million for the three months ended September 30, 2024 Disposable Protective Apparel decreased $58,000 or 1.1%, to $5.5 million, compared to $5.5 million for the same period of 2024Net income for the third quarter of 2025 was $976,000 or $0.09 per diluted share, compared to $862,000 or $0.08 per diluted share for the third quarter of 2024 Cash of $17.7 million and working capital of $48.1 million with no debt, as of September 30, 2025NOGALES, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) — Alpha Pro Tech,...

VANCOUVER, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) reported Adjusted EBITDA of negative $65.9 million in the third quarter of 2025, which included a non-cash export duty expense of $59.5 million related to the determination of final duty rates from the sixth Administrative Review (“AR”). In comparison, the Company reported Adjusted EBITDA of negative $10.7 million in the third quarter of 2024, which included a $1.0 million export duty recovery related to the determination of final duty rates from the fifth AR, and Adjusted EBITDA of $0.5 million in the second quarter of 2025. Net loss was $61.3 million in the third quarter of 2025, as compared to a net loss of $19.6 million in the third quarter of 2024, and net loss of $17.4 million in the second quarter...

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2025 and provided a corporate update. “We are continuing our strategic alternatives process with the goal of maximizing value for stockholders,” said Stephen Brady, president and chief executive officer of Tempest. “In addition, we look forward to the start of the TPST-1495 Phase 2 in collaboration with the NCI and the Cancer Prevention Clinical Trials Network and remain confident in the potential of amezalpat to transform the treatment of first-line HCC and bring meaningful benefit to patients and their families.” ——————  1 If approved...